Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Update

Hoth Therapeutics, Inc. (NASDAQ:HOTH) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 283,200 shares, an increase of 62.7% from the February 28th total of 174,100 shares. Approximately 2.2% of the shares of the stock are short sold. Based on an average daily volume of 8,500,000 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HOTH. D. Boral Capital reiterated a “buy” rating and set a $5.00 price objective on shares of Hoth Therapeutics in a research note on Monday, March 10th. HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Hoth Therapeutics in a research note on Thursday, January 23rd.

Hoth Therapeutics Stock Up 3.0 %

Shares of HOTH stock traded up $0.03 on Friday, reaching $1.03. The company had a trading volume of 136,303 shares, compared to its average volume of 3,426,124. The business’s 50-day moving average is $1.13 and its 200 day moving average is $1.01. Hoth Therapeutics has a one year low of $0.58 and a one year high of $3.80. The stock has a market capitalization of $7.11 million, a PE ratio of -0.78 and a beta of 0.84.

Hoth Therapeutics (NASDAQ:HOTH) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.07. On average, sell-side analysts forecast that Hoth Therapeutics will post -1.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hoth Therapeutics

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned about 0.47% of Hoth Therapeutics at the end of the most recent quarter. 7.08% of the stock is owned by hedge funds and other institutional investors.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.